29. Bhowmick S, Ravindran R, Ali N (2007) Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response. Vaccine 25: 6544–6556. 30. Mukhopadhyay S, Bhattacharyya S, Majhi R, De T, Naskar K, et al. (2000) Use of an attenuated leishmanial parasite as an immunoprophylactic and immunotherapeutic agent against murine visceral leishmaniasis. Clin Diagn Lab Immunol 7: 233–240. 31. Coffman RL, Lebman DA, Rothman P (1993) Mechanism and regulation of immunoglobulin isotype switching. Adv Immunol 54: 229–270. 32. Rosenkrands I, Weldingh K, Ravn P, Brandt L, Højrup P, et al. (1999) Differential T-cell recognition of native and recombinant Mycobacterium tuberculosis GroES. Infect Immun 67: 5552–5558. 33. Kemp M, Kurtzhals JA, Kharazmi A, Theander TG (1993) Interferon-gamma and interleukin-4 in human Leishmania donovani infections. Immunol Cell Biol 71: 583–587. 34. Campos-Neto A, Soong L, Cordova JL, Sant’Angelo D, Skeiky YA, et al. (1995) Cloning and expression of a Leishmania donovani gene instructed by a peptide isolated from major histocompatibility complex class II molecules of infected macrophages. J Exp Med 182: 1423–1433. 35. Coler RN, Reed SG (2005) Second-generation vaccines against leishmaniasis. Trends Parasitol 21: 244–249. 36. Martins DR, Jeronimo SM, Donelson JE, Wilson ME (2006) Leishmania chagasi T- cell antigens identified through a double library screen. Infect Immun 74: 6940–6948. 37. Bhatia A, Daifalla NS, Jen S, Badaro R, Reed SG, et al. (1999) Cloning, characterization and serological evaluation of K9 and K26: two related hydrophilic antigens of Leishmania chagasi. Mol Biochem Parasitol 102: 249–261. 38. Ghedin E, Zhang WW, Charest H, Sundar S, Kenney RT, et al. (1997) Antibody response against a Leishmania donovani amastigote-stage-specific protein in patients with visceral leishmaniasis. Clin Diagn Lab Immunol 4: 530–535. 39. Scott P, Artis D, Uzonna J, Zaph C (2004) The development of effector and memory T cells in cutaneous leishmaniasis: the implications for vaccine development. Immunol Rev 201: 318–338. 40. Heinzel FP, Schoenhaut DS, Rerko RM, Rosser LE, Gately MK (1993) Recombinant interleukin-12 cures mice infected with Leishmania major. J Exp Med 177: 1505–1509. 41. Afonso LC, Scharton TM, Vieira LQ, Wysocka M, Trinchieri G, et al. (1994) The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 263: 235–237. 42. Kamogawa Y, Minasi LA, Carding SR, Bottomly K, Flavell RA (1993) The relationship of IL-4- and IFN gamma-producing T cells studied by lineage ablation of IL-4-producing cells. Cell 75: 985–995. 43. Platzer C, Richter G, Uberla K, Muller W, Blocker H, et al. (1992) Analysis of cytokine mRNA levels in interleukin-4-transgenic mice by quantitative polymerase chain reaction. Eur J Immunol 22: 1179–1184. 44. D’Andrea A, Ma X, Aste-Amezaga M, Paganin C, Trinchieri G (1995) Stimulatory and inhibitory effects of interleukin (IL)-4 and IL-13 on the production of cytokines by human peripheral blood mononuclear cells: priming for IL-12 and tumor necrosis factor alpha production. J Exp Med 181: 537–546. Novel Antigens of L. donovani 45. Alexander J, Carter KC, Al-Fasi N, Satoskar A, Brombacher F (2000) Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. Eur J Immunol 30: 2935–2943. 46. Rafati S, Gholami E, Hassani N, Ghaemimanesh F, Taslimi Y, et al. (2007) Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients. Vaccine 25: 4159–4169. 47. Ma˚len H, Berven FS, Søfteland T, Arntzen MØ, D’Santos CS, et al. (2008) Membrane and membrane-associated proteins in Triton X-114 extracts of Mycobacterium bovis BCG identified using a combination of gel-based and gel-free fractionation strategies. Proteomics 8: 1859–1870. 48. Connolly JP, Comerci D, Alefantis TG, Walz A, Quan M, et al. (2006) Proteomic analysis of Brucella abortus cell envelope and identification of immunogenic candidate proteins for vaccine development. Proteomics 6: 3767–3780. 49. Gupta SK, Sisodia BS, Sinha S, Hajela K, Naik S, et al. (2007) Proteomic approach for identification and characterization of novel immunostimulatory proteins from soluble antigens of Leishmania donovani promastigotes. Proteomics 7: 816–823. 50. Jones A, Faldas A, Foucher A, Hunt E, Tait A, et al. (2006) Visualisation and analysis of proteomic data from the procyclic form of Trypanosoma brucei. Proteomics 6: 259–267. 51. Tabatabai LB, Zehr ES (2004) Identification of five outer membrane-associated proteins among cross-protective factor proteins of Pasteurella multocida. Infect Immun 72: 1195–8. 52. Probst P, Stromberg E, Ghalib HW, Mozel M, Badaro R, et al. (2001) Identification and characterization of T cell-stimulating antigens from Leishmania by CD4 T cell expression cloning. J Immunol 166: 498–505. 53. Theinert SM, Basu R, Forgber M, Roy S, Sundar S, et al. (2005) Identification of new antigens in visceral leishmaniasis by expression cloning and immuno- blotting with sera of kala-azar patients from Bihar, India. Infect Immun 73: 7018–7021. 54. Rosenzweig D, Smith D, Myler PJ, Olafson RW, Zilberstein D (2008) Post- translational modification of cellular proteins during Leishmania donovani differentiation. Proteomics 8: 1843–1850. 55. Campbell K, Diao H, Ji J, Soong L (2003) DNA immunization with the gene encoding P4 nuclease of Leishmania amazonensis protects mice against cutaneous leishmaniasis. Infect Immun 71: 6270–6278. 56. Carrillo E, Crusat M, Nieto J, Chicharro C, Thomas Mdel C, et al. (2008) Immunogenicity of HSP-70, KMP-11 and PFR-2 leishmanial antigens in the experimental model of canine visceral leishmaniasis. Vaccine 26: 1902–1911. 57. Qazi KR, Oehlmann W, Singh M, Lo´pez MC, Ferna´ndez C (2007) Microbial heat shock protein 70 stimulatory properties have different TLR requirements. Vaccine 25: 1096–1103. 58. Skeiky YAW, Benson DR, Guderian JA, Whittle JA, Bacelar O, et al. (1995) Immune responses of leishmaniasis patients to heat shoch proteins of Leishmania species and human. Infect Immun 63: 4105–4114. PLoS ONE | www.plosone.org 10 June 2009 | Volume 4 | Issue 6 | e5820